JPH07101859A - Mutagenic inhibitor - Google Patents

Abstract

PURPOSE:To provide the inhibitor exhibiting a good inhibiting action against mutagenic substances contained in daily environments such as the atmosphere or foods and capable of being ingested into bodies as a medicine or a specific healthy food for the prevention of cancers because having extremely high safety. CONSTITUTION:The mutagenic inhibitor contains at least a trihydric phenolic substance selected from dillapiole, apiole and myristicin. The trihydric phenolic substance can be recovered from the essential oils of Petroselinum crispum and/or Anethum graveolens L. and subsequently used.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to a mutagenicity inhibitor, the purpose of which is to show a good activity-inhibiting effect on mutagens present in the environment such as food, air, and feces, and its safety. Therefore, it is intended to provide a mutagenicity inhibitor that can be appropriately ingested daily as a drug or a specified health food for the purpose of cancer prevention.

[0002]

2. Description of the Related Art The mortality rate due to cancer in Japan has been the highest for several years, even after stroke. Cancer is different from bacterial infections, in that the cells that form the solid itself change into cancer cells by some mechanism, and they grow endlessly, and as a result, the individual eventually die. Is. With recent advances in epidemiological studies, it is becoming more and more recognized that most of human cancers are caused by chemical carcinogens in the environment. That is, it is considered that most human cancers are not caused by viruses but are caused by damage to somatic genes by chemical carcinogens existing in the environment. Many chemical carcinogens are DNA themselves or their metabolic activators.
It is a mutagen that modifies. A mutagen is a chemical substance that induces a mutation at a higher rate than a mutation that naturally occurs in an organism, and is a base pair substitution type mutagen that changes one of the base pairs in DNA to another base pair. It is classified as a frameshift type mutagen that adds or deletes base pairs.

Many mutagens are present in our environment. As a mutagen, 3,4-benzpyrene contained in cigarette smoke and exhaust gas from automobiles has been well known. In addition, recently, Am that predicts carcinogenicity by using bacterial mutagenicity as an index
With the spread of the es method, various carcinogens and mutagenic substances have been found in the environment such as food and air. As a specific example, it has been reported that, in cooked meat and fish products, the heating of amino acids and proteins produces a mutagen having a higher activity than benzpyrene. For example, from tryptophan, 3-amino-1,4-dimethyl-5H-pyrido [4,3-b] indole (Trp-P-1) and 3-amino-1-methyl-5H-pyrido [4,3- b]
Indole (Trp-P-2) was converted from glutamic acid to 2-amino-6-methyldipyrido [1,2-α: 3 ′,
2′-d] imidazole (Glu-P-1) and 2-amino-6-dipyrido [1,2-α: 3 ′, 2′-d] imidazole (Glu-P-2) are respectively produced by heating. Has been reported. It has also been reported that mutagenic precursors are present in foods such as broad beans and soy sauce. On the other hand, powerful mutagens such as 1-nitropyrene and 1,6-nitropyrene have been detected in diesel exhaust gas. Furthermore, mutagenic substances such as fecapentaene-12 and fecapentaene-14 have been detected in human feces.

[0004]

As described above, strong mutagens are being detected one after another in foods, air, faeces, etc., which are closely related to our daily lives. However, these foods and air are indispensable for our lives. Therefore, in the industry, it is possible to suppress the mutagenicity of cells caused by the mutagen, and for the purpose of preventing or controlling cancer, a highly safe mutagenicity inhibitor that can be effectively used as a drug or a food for specified health uses. The creation of agents was desired.

[0005]

The present invention provides a mutagenic inhibitor characterized by comprising at least one trihydric phenol substance selected from diluapiol, apiol and myristin as an active ingredient. , The above-mentioned conventional problems are solved.

[0006]

BEST MODE FOR CARRYING OUT THE INVENTION The constitution of the mutagenicity inhibitor according to the present invention will be described in detail below. In the present invention, at least one trihydric phenol substance selected from diluapiol, apiol and myristicin is used as an active ingredient. Diluapiol is a trihydric phenol represented by the general formula 1 (Formula 1), and is a genus of Anethum A. graveolens.
L. (Dill), A. Sowa DC (Indian Dill), P. angustifolium Ruizet of the genus Pepper
Pavon (matico), or Crithmun maritimum L. (sea
fennel), a substance contained in the essential oil obtained from M. formosana Maxim .

[Chemical 1]

Starting materials for obtaining diluapiol include whole plants, leaves, stems, flowers,
It can be used in any part such as the seed part, and any of those recovered from the essential oil in these parts is preferably used, but the inondo (Anethu) used as a spice is used.
m) Genus A. graveolens L. (Dill) or A. Sowa DC
(Indian dill) whole plant or seed essential oil (Di
ll Oil) can be more preferably used from the viewpoint of recovery rate and the like. Here, A. graveolens L. (dill) is the Japanese name for inondo, which is an annual grass of the Unbelliferae family native to the southern Soviet Union on the Mediterranean coast, with a plant height of 60.
〜150cm, the stem is erect and branched, the leaves are divided like feathers, the debris is elongated linear, and it is a plant with florets at the end of branches and yellow floret in summer. The fruit also has a flat oval shape and consists of two fused carpels, each carcass containing one seed.

Apiol is a trihydric phenol represented by the general formula 2 (Chemical formula 2), and P. crispum (Mill.) (Parsley) and pepper (Piper) belonging to the genus Petroselinum of the family Umbelliferae . Genus P. angustifolium Ruizet
It is a substance contained in the essential oil obtained from Pavon (matico) .

[Chemical 2]

The starting material for obtaining apiol can be suitably used in any part of the plant such as whole grass, leaves, stems, flowers and seeds, and apiol recovered from the essential oil in these parts. Although any of these can be preferably used, the Dutch seri (Petroselinum) genus P. crispum (Mil
l.) (Parsley), which is obtained from the essential oil of the leaf part or seed part, can be more preferably used from the viewpoint of recovery rate and the like. Here, P. crispum (Mill.) (Parsley) means the Umbellife (Umbellife) native to the eastern Mediterranean region and central and northern Europe.
(rae) It is a so-called biennial grass, which has many branches from a stem with a height of 30 to 60 cm in a groove, leaves are bright dark green with a long handle, Sanje compound leaves are attached, and it has a distinctive aroma. It is a widely used plant for plants.

Further, myristicin is represented by the general formula 3
It is a trihydric phenol represented by
selinum) P. crispum (Mill.) (parsley), Inondo (Ane
thum) Genus A. graveolens L. (Dill) or A. Sowa D.
C. (Indian dill) or Salvia plebeia R.
Essential oil obtained from (Mizoukouju) or nutmeg (M
yristicaceae) is a substance contained in essential oils such as nut meg oil and mace oil.

[Chemical 3]

As the starting material for obtaining myristicin, any part of the above plant such as whole grass, leaves, stems, flowers and seeds can be preferably used, and myristicin recovered from the essential oil in these parts. Can be preferably used, but the Dutch seri (Petroselinum) genus P. crispum (Mi
ll.) (parsley), genus Anethum (Anethum) A. graveolens
What is contained in the essential oil of L. (dill) or A. Sowa DC (Indian dill), or Salvia plebeia R. (Mizoukouju) can be more preferably used from a viewpoint of recovery rate.

The method for obtaining the essential oil from the above-mentioned plants is not particularly limited, and includes steam distillation method, squeezing method, extraction method with polar solvent or non-polar solvent, redistillation (vacuum distillation), Any known method such as adsorption or distribution can be used without limitation. On the other hand, the above-mentioned trihydric phenols used as the active ingredient in the present invention are not limited to those obtained from plant essential oils, and synthetic products can also be suitably used.

At least one of 3 obtained from diluapiol, apiol and myristicin as described above.
A polyphenol as an active ingredient can be used as the mutagenicity inhibitor according to the present invention. The dosage form of this mutagenicity inhibitor may be in the form of solution, soft extract, or powder, and is not particularly limited. Also, this dosage form is not particularly limited, and drugs such as powders, granules, tablets, capsules, and syrups are added in accordance with the usual method of preparation production by appropriately adding arbitrary excipients and adjuvants. Or as a food for specified health use that is expected to have a mutagenicity-suppressing effect, it may be a drink, a drink such as juice, a confectionery, or other food, and is not particularly limited.

[0014]

[Examples] Hereinafter, by giving examples and test examples,
The effect of the mutagenicity inhibitor of the present invention will be further clarified. However, the present invention is not limited to the following embodiments. (Example 1) [Indian dill (Anethum sowa DC )
Isolation of diluapiol from seed] Commercial Indian dil
l Seed was pulverized by a crusher, and 500 g of the seed was put into a 5 liter capacity corpen, and 2 liters of water was added thereto. In this state, steam distillation is performed according to the usual method to obtain 9 kg.
Was obtained. The oil separated in the upper layer is separated, and Indian
I got dill seed oil. Said Indian dill seed oil 4.0
g for silica gel [trade name; Silica gel 60 No.5385, (Mer
(manufactured by ck Co., Ltd.)] After being adsorbed on 6.0 g, a dry powder was obtained. A dry column prepared in advance [filler: silica gel 200 g / including 2.0% UV indicator
, 80 × 80 cm nylon column was used) to fully stabilize it. At this time, the developing solvent used was normal hexane: ethyl acetate = 95: 5. When the tip of the developing solvent reaches the bottom of the column, the development is stopped, and the part corresponding to the diluapiol that was previously confirmed [ultraviolet (254 nm)
The separated band confirmed by irradiation with a) was cut with a knife or the like and extracted with 99% ethanol. The obtained extract was subjected to gravity filtration (ToYo No. 24A) and then concentrated under reduced pressure to obtain a crude oil. This crude oil was purified by preparative thin layer chromatography (the developing solvent used was normal hexane: ethyl acetate = 95: 5 as in the dry column method). The obtained preparative substance was naturally filtered in the same manner as above, concentrated, and then extracted with diethyl ether to remove silica gel. The extract was filtered and then concentrated to obtain 442.0 mg of diluapiol (purity 98.4%). The resulting diluapiol was used as the component of Example 1. The identification of diluapiol was carried out by gas chromatography analysis and GC-MS analysis. Analysis conditions are gas chromatograph [HP 5
890 (manufactured by Hewlett Packrad)], column [DB WAXO 25 ×
30m (manufactured by J & W)], column temperature 60-230 ° C (3 ° C / min.),
Detector: FD, sprit ratio; 100: 1. The result of gas chromatographic analysis of the obtained diluapiol is shown in FIG.

(Example 2) [Isolation of apiol from Parsley leaf oil] Commercially available Pa
4.0g of rsley leaf oil 810420 (Flavador) is silica gel (trade name; Silica gel 60 No.5385 (Merck))
After being adsorbed on 6.0 g, it was made into a dry powder. A dry column prepared in advance [filler: silica gel 200 g / including 2.0% UV indicator, 80 × 80
cm nylon column was used) to sufficiently stabilize it. Five same columns as this column were prepared and developed using a solvent of normal hexane: ethyl acetate = 95: 5. When the tip of the developing solvent reaches the bottom of the column, the development is stopped, and the myristin, which has been confirmed in advance, the portion corresponding to apiol (the separation band confirmed by irradiation with ultraviolet rays (254 nm)) is cut with a knife or the like, Extracted with 99% ethanol. The resulting extract is gravity filtered (ToYo No.2 4A
After that, the mixture was concentrated under reduced pressure. This concentrated solution was again subjected to the same dry column chromatography as described above, and the portion corresponding to apiol was collected as described above and extracted with 99% ethanol. The extract was naturally filtered, concentrated under reduced pressure, and purified by preparative thin-layer chromatography (developing solvent was normal hexane: ethyl acetate = 95: 5 as in the dry column method). The obtained preparative substance was naturally filtered in the same manner as above, concentrated, and then extracted with diethyl ether to remove silica gel. The extract was filtered and then concentrated to obtain 89.0 mg of apiol (purity 96.23%). The obtained apiol was used as the component of Example 2. The apiol was identified by gas chromatographic analysis and GC-MS analysis (analytical conditions were the same as in Example 1). The results of gas chromatographic analysis of apiol obtained from Parsley leaf oil are shown in FIG.

(Example 3) [Isolation of myristicin from Parsley leaf oil] commercially available
Parsley leaf oil 810420 (manufactured by Flavador) 4.0 g of silica gel (trade name; Silica gel 60 No.5385 (manufactured by Merck))
After being adsorbed on 6.0 g, it was made into a dry powder. A dry column prepared in advance [filler: silica gel 200 g / including 2.0% UV indicator, 80 × 80
cm nylon column was used) to sufficiently stabilize it. Five same columns as this column were prepared and developed using a solvent of normal hexane: ethyl acetate = 95: 5. When the tip of the developing solvent reaches the bottom of the column, the development is stopped, and the portion corresponding to myristicin that was confirmed in advance (separation band confirmed by irradiation with ultraviolet rays (254 nm)) was cut with a knife, etc., and 99% Extracted with ethanol. The obtained extract was subjected to gravity filtration (ToYo No. 24A) and then concentrated under reduced pressure. This concentrated liquid was purified by preparative thin layer chromatography (the developing solvent used was normal hexane: ethyl acetate = 95: 5 as in the dry column method). The obtained preparative substance was naturally filtered in the same manner as above, concentrated, and then extracted with diethyl ether to remove silica gel. The extract is filtered and concentrated to give myristicin 49
3.0 mg (purity 98.1%) was obtained. The obtained myristicin was used as the component of Example 3. The identification of myristicin was performed by gas chromatography analysis and GC-MS analysis. The results of gas chromatographic analysis of myristicin obtained from Parsley leaf oil are shown in Fig. 3, respectively.

Comparative Example 1 Safrole (commercial product; manufactured by Kanto Kagaku Co., Ltd.), which is a kind of plant essential oil, was used as a component of Comparative Example 1. (Comparative Example 2) Carvone which is a kind of plant essential oil (commercial product;
GIVAUDAN Co., Ltd. was used as the component of Comparative Example 2.

[0018]

[Test example]

(1) Pharmacological test (mutagenicity suppression test) The mutagenicity suppression test is an inhibitory effect on the mutagen Trp-P-2 detected from charred foods using a histidine (His) -requiring Salmonella TA98 strain. Was used as an index. [Ames variant (plate method); His - test if it causes a reverse mutation to His ⁺ mutants of Salmonella ^(unable to synthesize histidine) by contact with the specimen] Further, mutagen Trp-P -2 undergoes metabolic activation to become N-OH-Trp-P-2, which is known to exhibit mutagenicity. Therefore, the metabolic activation enzyme S9-m
The test was conducted by adding ix.

A) Preparation of Salmonella TA98 strain Preparation of SDB liquid medium NaCl 0.5 g, Bacto nutrient broth (Difco) 0.8 g 10
It was dissolved in 0 ml of distilled water, adjusted to pH 7.0 and sterilized in an autoclave. Inoculation / enrichment Salmonella TA98 in the sterilized SDB liquid medium
0.2 ml of the stock solution was added to inoculate the cells, and the cells were cultured at 37 ° C for 18 hours with shaking to enrich the cells. Preparation and storage TA98 bacterial culture was centrifuged (0 ℃, 3,500rpm, 15
The cells were separated for 11 minutes using an 11 cm rotor). The dilution ratio of all the solutions was determined so that the OD value was 0.5, and the solution was diluted with phosphate buffer and dimethylsulfoxide (DMSO) (final concentration 12%). This diluted solution was placed in a 4 ml vial and stored at -80 ° C until the mutagenicity inhibition test was performed. This is TA9
Eight bacterial stock solutions were used.

B) Preparation of MBB agar medium (MBB agar medium formulation) i. Bacto ager (Difco) 30 g distilled water 1,860 g ii. MM (Modified Voger Bonner's 20X) medium (NH ₄ ) ₂ SO ₄ 20 g KH ₂ PO ₄ 200g MgSO ₄・ 7H ₂ 0 2g Na ₃ C ₆ H ₅ O ₇ (Sodium citrate) 10g KOH 34.5g / 900ml (* Adjust the total volume to 1 liter after adjusting pH to 7.0 with KOH aqueous solution) iii.DB solution Bacto nutrient broth (Difco) 400ml Distilled water 40ml (* Adjusted to pH 6.8 to 7.0) iv.40% Glucose solution Glucose (Anhydrous) 20g Distilled water 30ml v.Biotin solution Biotin 4mg Srerilized water 40ml (* Prepared for use) (MBB Agar Medium Preparation Method) After the above i to iv were prepared, they were separately sterilized in an autoclave. After v was prepared, it was sterilized by filtration in a clean bench. After cooling the i to about 70 ° C., ii 100 ml, iii 2
0 ml, iv 20 ml and v 2 ml were added aseptically and mixed well. About 25 ml of the above medium was poured into a 9 cm dish that had been sterilized by heat in advance to prepare a plate medium. After air-drying the surface of the plate medium, it was stored for 1 day or more until it was used for a mutagenicity inhibition test.

C) Mutagenicity Inhibition Test In 3.0 ml of soft agar (* 1) kept at 50 ° C., 100 μl of the component (* 2) of the above Examples and Comparative Examples,
100 μl of thawed Salmonella TA98 stock solution
100 μl of 1.5 μg / ml p-P-2 aqueous solution, S-
MBB prepared in advance after adding 9 mix (rat liver extract) (* 3) 500 μl each and stirring rapidly
Spread on agar. Similarly, 10 parts of dimethyl sulfoxide (DMSO) was used instead of the components of the above-mentioned Examples and Comparative Examples.
The same procedure was carried out with 0 μl added, and this was used as a control.
Three plates of each sample were prepared and cultured at 37 ° C. for 3 days. After culturing, the reverse mutation His ⁺ revart
The number of rant colonies was measured and the average was used to calculate
The mutation suppression rate was calculated based on (1). The results are shown in Table 1. * 1: NaCl 3.0g, Ager 3.5g dissolved in 500ml distilled water, sterilized by autoclave and kept at 50 ° C * 2: DMSO was used to dilute each component * 3: S-9 ( Oriental Yeast Co., Ltd. (* 3-1) 1 ml of Cofactor-I (Oriental Yeast Co., Ltd. (* 3-2)) dissolved in 9 ml of distilled water was sterilized by filtration. * 3-1: As an inducer, phenobarbital (PB) and 5,
Supernatant fraction obtained by homogenizing rat male liver co-administered with 6-benzoflavone (BF) and centrifuging at 9,000 × g * 3-2: Composition MgCl ₂ / 6H ₂ O 16.3mg NADH 30.5mg KCl 24.6 _{mg NA 2 HPO 4 119.6mg G-} 6-P 17.0mg NAH 2 PO 4 · 2H 2 O 24.7mg NADPH 36.2mg C: number of colonies in the control of His ⁺ revartrant S: number of colonies His ⁺ revartrant of each sample

[0022]

[Table 1]

D) Viable cell count test 1 Salmonella TA98 stock solution with phosphate buffer (* 4)
^Serially diluted to 0-5. In 3.0 ml of soft agar (* 5) kept at 50 ° C., 100 μl of the components obtained in each of the examples and comparative examples and 100 μl of this diluted solution (D
(Diluted with MSO) was added, and the mixture was quickly stirred and then spread on an MBB agar plate medium prepared in advance. Similarly, dimethyl sulfoxide (DM
100 μl of SO) was added and used as a control.
Three plates of each sample were prepared and cultured at 37 ° C. for 3 days. After culturing, the number of viable bacteria was measured, the average thereof was determined, and the presence or absence of toxicity of the components of each Example and Comparative Example to Salmonella TA98 was tested. The results are shown in Table 2. * 4: Dissolve 14.3g of Na ₂ PO ₄ · 12H ₂ O and 3.6g of KH ₂ PO _{4 in} 1 liter of distilled water and adjust to pH 7.0 * 5: 3.0g of NaCl and 3.5g of Ager in 500ml of distilled water Dissolved in, sterilized by autoclave, and kept at 50 ℃

[0024]

[Table 2]

As is clear from the results shown in Table 1, Examples 1 to 1
It is understood that all of the components of 3 have a mutagenicity-suppressing action, and that diluapiol of Example 1 has a particularly high inhibiting action. Further, the components of Comparative Examples 1 and 2 were substances recovered from the plant essential oil, but no mutagenicity-suppressing activity was observed. As is clear from the results in Table 2, no toxicity to Salmonella TA98 was observed in any of the components of Examples and Comparative Examples.

[0026]

As described in detail above, since the present invention is a mutagenic inhibitor characterized by comprising at least one trihydric phenolic substance of diluapiol, apiol and myristin as an active ingredient, As is clear from the results of the above-mentioned test examples, it has a good inhibitory action on mutagenic substances present in foods and air that are deeply related to our daily lives, and its safety is also extremely high. Also, it has an excellent effect that it can be used as a medicine or a food for specified health use and taken into the body for the purpose of preventing cancer.

[Brief description of drawings]

FIG. 1 is a GC-MS showing diluapiol of Example 1.
It is a chart figure of an analysis.

FIG. 2 is a GC-MS analysis chart showing apiol of Example 2.

FIG. 3 is a GC-MS analysis chart showing myristicin of Example 3.

─────────────────────────────────────────────────── ───

[Procedure amendment]

[Submission date] March 17, 1994

[Procedure Amendment 1]

[Document name to be amended] Statement

[Name of item to be corrected] Claim 1

[Correction method] Change

[Correction content]

[Procedure Amendment 2]

[Document name to be amended] Statement

[Name of item to be corrected] Claim 2

[Correction method] Change

[Correction content]

[Procedure 3]

[Document name to be amended] Statement

[Correction target item name] 0006

[Correction method] Change

[Correction content]

[0006]

BEST MODE FOR CARRYING OUT THE INVENTION The constitution of the mutagenicity inhibitor according to the present invention will be described in detail below. In the present invention, at least one substance selected from diluapiol, apiol and myristicin is used as the active ingredient. Diluapiol is a substance represented by the general formula 1 (Chemical formula 1), and A. graveolens
L. (Dill), A. Sowa D. C. (Indian dill), P. of pepper genus angu
stifolium Ruizet Pavon (ma
tico), or Crithmun maritim
um L. (Sea fennel), M.A. formo
sana Maxim . (Taiwan Himediso), Foe
nicum vulgare will
It is a substance contained in the essential oil obtained from the etc.

[Chemical 1]

[Procedure amendment 4]

[Document name to be amended] Statement

[Correction target item name] 0008

[Correction method] Change

[Correction content]

Apiol is a substance represented by the general formula 2 (Chemical Formula 2), and it is a substance such as Umbelliferae.
P. of the genus Petroselinum of the family Netherlands
crispum (Mill.) (parsley), P. of pepper genus . angustifolium
It is a substance contained in the essential oil obtained from Ruizet Pavon (matico).

[Chemical 2]

[Procedure Amendment 5]

[Document name to be amended] Statement

[Correction target item name] 0010

[Correction method] Change

[Correction content]

Further, myristicin is represented by the general formula 3
It is a substance represented by
Linum) genus P. crispum (Mill.) (parsley), Anethum genus A. grave
olens L. (Dill) or A. Sowa D.
C. (Indian dill) or Salvia p
lebeia R. (Mizo Kouju), America
Cormorant (Pastinacasativa L.) essential oil obtained from, or nutmeg (Myristicacea
It is a substance contained in the essential oil such as nutmeg oil obtained from e).

[Chemical 3]

[Procedure correction 6]

[Document name to be amended] Statement

[Correction target item name] 0012

[Correction method] Change

[Correction content]

The method for obtaining the essential oil from the above-mentioned plants is not particularly limited, and includes steam distillation, compression method, extraction method with polar solvent or non-polar solvent, redistillation (vacuum distillation), adsorption. Commonly known methods such as distribution can be used without limitation. On the other hand, as the above-mentioned three kinds of substances used as the active ingredients in the present invention, synthetic products can be suitably used in addition to those obtained from plant essential oils.

[Procedure Amendment 7]

[Document name to be amended] Statement

[Correction target item name] 0013

[Correction method] Change

[Correction content]

At least one substance obtained from diluapiol, apiol and myristicin as described above .
With the quality as an active ingredient, the mutagenicity inhibitor according to the present invention can be used. The dosage form of this mutagenicity inhibitor may be in the form of solution, soft extract, or powder, and is not particularly limited. Also, this dosage form is not particularly limited, and appropriately added with any excipients, auxiliaries and the like, and according to a conventional method for manufacturing a preparation, a powder, granules, tablets,
It may be a drug such as a capsule or a syrup, or as a food for specified health use expected to have a mutagenicity-suppressing effect
It may be a drink, a drink such as juice, confectionery, or other food, and is not particularly limited.

[Procedure Amendment 8]

[Document name to be amended] Statement

[Correction target item name] 0026

[Correction method] Change

[Correction content]

As described above in detail, since the present invention is a mutagenicity inhibitor characterized by comprising at least one substance selected from diluapiol, apiol and myristicin as an active ingredient, the results of the above test examples As can be seen from the above, it has a good inhibitory action against mutagenic substances present in foods and air that are deeply related to our daily lives, and its safety is extremely high, so it is necessary to prevent cancer. It has an excellent effect that it can be used as a medicine or a food for specified health purposes and can be inoculated into the body.

Claims (3)

[Claims] 1. A mutagenic inhibitor comprising at least one trihydric phenolic substance selected from diluapiol, apiol and myristicin as an active ingredient. 2. The mutagenic inhibitor according to claim 1, wherein the trihydric phenol substance is a substance obtained from plant essential oil. 3. The plant essential oil is parsley (Petroselinum cr
The mutagenic inhibitor according to claim 2, which is an essential oil obtained from ispum) and / or dill (Anethum graveolens L.).